BSc, MSc, PhD
My research seeks to incorporate genomics into guiding, optimising, and developing novel therapeutics to improve the safety and effectiveness of medications. In terms of using genomics to develop new drugs, I developed a novel gene-delivery treatment for LPL Deficiency, a severe genetic disorder of lipid metabolism, which recently became one of the first gene-based therapies to receive regulatory approval. My research is also exploring the use of genome sequencing to help diagnose and manage the treatment of rare genetic diseases. Towards the optimisation of existing medications, my research is largely focused on the identification and implementation of genomic factors that are predictive of an individual patient’s response to a medication. The debilitating and sometimes lethal consequences of severe adverse drug reactions are a striking problem in modern medicine. The consequences for patients who experience severe ADRs can be catastrophic. I helped establish the ‘Canadian Pharmacogenomics Network for Drug Safety’ (CPNDS), a network of clinicians and researchers in hospitals across Canada to identify patients that have suffered severe ADRs with the goal of developing and implementing genomics-based predictive pharmacogenomic tests to help optimize individual drug treatment.
"2016 MSFHR Scholar Award". Michael Smith Foundation for Health Research (MSFHR). May 2016.
"2016 BC Children's Hospital Investigator IGAP Award", BC Children's Hospital Child & Family Research Institute. March 2016.
"2012 CIHR New Investigator Award". Canadian Institutes of Health Research. July 2012.
"2011 Champions of Genetics, New Investigator Award". Canadian Gene Cure Foundation.
"Clinical and Pharmacogenomics predictors of inter-patient variation in Direct Acting Oral Anticoagulant (DOAC) plasma concentrations in real-world patients." Co-PI with Richard Kim, UWO. $497,405. CIHR Drug Safety & Effectiveness Network. 2015-2017
"DSEN-PREVENT - Pharmacogenomics of Adverse Reaction EVEnts Nation-wide Team Grant" Co-PI with Carleton and Kim $750,000 (2014-2018)
"hiPSC-Cardiomyocytes to Screen Variants Predictive of Doxorubicin Cardiotoxicity". $380,000 National Institutes of Health (NIH). Co-I with PI: Dan Bernstein, Stanford University. (2014-2019)
"Identification of pharmacogenomic variants for the prevention of vincristine-induced neurotoxicity". $99,866. CIHR. (2013-2015)
"Personalized genomic medicine for improved paediatric drug safety and Effectiveness. PI. $309,743. Canada Foundation for Innovation.